VACCITECH PLC (VACC)
US91864C1071 - ADR
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the week with a breakdown of the biggest pre-market stock movers that investors need to know about for Monday!
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
/PRNewswire/ -- FinancialNewsMedia.com News Commentary - There has been a rise in the prevalence of cancer in the past several years. Overall, there is a rapid...
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the...
Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the...
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
Meaningful, durable reductions of HBsAg were seen, both in participants who received VTP-300 alone and in combination with a low-dose PD-1 inhibitorTwo...
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy
OXFORD, United Kingdom, June 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical...
Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments
OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company...
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
Amid the noise of the global markets recently, these speculative biotech stocks to buy might trade with a mind of their own.
Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B
Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B
Completed Phase 1b/2a trial of VTP-300 met its primary and secondary endpointsVTP-300 is the first antigen-specific immunotherapy shown to induce sustained...
Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments
Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments
OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical...